We explore new strategies for the treatment of Parkinson’s disease (PD) and related synucleinopathies such as Dementia with Lewy bodies (DLB). These diseases are characterized by the aggregation of the protein α-synuclein (αS), an abundant nerve cell component in the brain. With no disease-modifying drugs available, there is a great need for robust models that recapitulate how early changes in the normal maintenance of α-synuclein can lead to these aggregates. Combining cell biology, biochemistry, microscopy, high-content imaging and screening approaches, we want to:

  • understand normal αS cell biology,
  • define abnormal αS states,
  • transform abnormal αS states into screenable phenotypes,
  • use the correction of abnormal states as a readout for drug discovery.

Current Lab Members

Nagendran Ramalingam, PhD

Nagendran Ramalingam, PhD

Research Fellow
Thibaut Imberdis, PhD

Thibaut Imberdis, PhD

Research Fellow
Liz Kantor, BA

Liz Kantor, BA

Research Technician
Arati Tripathi, PhD

Arati Tripathi, PhD

Research Fellow
Ulf Dettmer, PhD

Ulf Dettmer, PhD